Adaptimmune Therapeutics Plc (ADAP)

1.43
0.01 0.69
NASDAQ : Health Technology
Prev Close 1.44
Open 1.44
Day Low/High 1.40 / 1.55
52 Wk Low/High 1.44 / 14.54
Volume 290.89K
Avg Volume 281.70K
Exchange NASDAQ
Shares Outstanding 104.71M
Market Cap 150.81M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Adaptimmune To Report Second Quarter 2019 Financial Results And Business Update On Thursday, August 1, 2019

Adaptimmune To Report Second Quarter 2019 Financial Results And Business Update On Thursday, August 1, 2019

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 29, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results for the Second Quarter 2019 and provide a business update...

Adaptimmune Starts SPEARHEAD-1 Trial With ADP-A2M4 SPEAR T-cells For Patients With Synovial Sarcoma Or MRCLS

Adaptimmune Starts SPEARHEAD-1 Trial With ADP-A2M4 SPEAR T-cells For Patients With Synovial Sarcoma Or MRCLS

- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc...

Adaptimmune Has Initiated A Radiation Sub-Study To Enhance Antitumor Activity Seen With ADP-A2M4 In Collaboration With The MD Anderson Cancer Center

Adaptimmune Has Initiated A Radiation Sub-Study To Enhance Antitumor Activity Seen With ADP-A2M4 In Collaboration With The MD Anderson Cancer Center

- Compelling responses previously reported with ADP-A2M4 in sarcoma - - Use of low-dose radiation intended to enhance antitumor activity - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc...

Adaptimmune Starts The SURPASS Clinical Trial With Its First Next-Generation SPEAR T-cells Targeting MAGE‑A4 To Enhance Antitumor Responses

Adaptimmune Starts The SURPASS Clinical Trial With Its First Next-Generation SPEAR T-cells Targeting MAGE‑A4 To Enhance Antitumor Responses

These next-generation SPEAR T-cells may improve long term T-cell functions

First Week Of ADAP February 15th Options Trading

First Week Of ADAP February 15th Options Trading

Investors in Adaptimmune Therapeutics PLC saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADAP options chain for the new February 15th contracts and identified the following put contract of particular interest.

January 2019 Options Now Available For Adaptimmune Therapeutics (ADAP)

January 2019 Options Now Available For Adaptimmune Therapeutics (ADAP)

Investors in Adaptimmune Therapeutics PLC saw new options begin trading today, for the January 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 87 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

RSI Alert: Adaptimmune Therapeutics (ADAP) Now Oversold

RSI Alert: Adaptimmune Therapeutics (ADAP) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Adaptimmune Therapeutics Breaks Above 200-Day Moving Average - Bullish For ADAP

Adaptimmune Therapeutics Breaks Above 200-Day Moving Average - Bullish For ADAP

In trading on Friday, shares of Adaptimmune Therapeutics PLC crossed above their 200 day moving average of $9.97, changing hands as high as $10.50 per share. Adaptimmune Therapeutics PLC shares are currently trading up about 8.9% on the day.

Relative Strength Alert For Adaptimmune Therapeutics

Relative Strength Alert For Adaptimmune Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of ADAP March 2019 Options Trading

First Week Of ADAP March 2019 Options Trading

Investors in Adaptimmune Therapeutics PLC saw new options begin trading this week, for the March 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Relative Strength Alert For Adaptimmune Therapeutics

Relative Strength Alert For Adaptimmune Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CODA, ENV, JP, RFIL, SPB, WYND Downgrades: ADAP, AOSL, ATAI, AVH, ELF, RM, TEO, ZUMZ Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Consolidated Edison, Chesapeake Energy: 'Mad Money' Lightning Round

Consolidated Edison, Chesapeake Energy: 'Mad Money' Lightning Round

Jim Cramer weighs in on Consolidated Edison, Clorox, Chesapeake Energy, Adaptimmune Therapeutics, Icahn Enterprises, Bristol-Meyers Squibb and more.

Where the Bears Are: Cramer's 'Mad Money' Recap (Tuesday 5/15/18)

Where the Bears Are: Cramer's 'Mad Money' Recap (Tuesday 5/15/18)

Get ahead of the naysayers, says Jim Cramer. FANG and other tech leaders have gone cold, but they're not dead yet.

Interesting ADAP Put And Call Options For December 21st

Investors in Adaptimmune Therapeutics PLC saw new options begin trading this week, for the December 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 225 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Adaptimmune Therapeutics Reaches Analyst Target Price

In recent trading, shares of Adaptimmune Therapeutics PLC have crossed above the average analyst 12-month target price of $13.40, changing hands for $13.74/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

4 Strong Buy Biotech Stocks Poised to Explode

4 Strong Buy Biotech Stocks Poised to Explode

Here comes the growth. These four strong buy biotech stocks are potentially on the cusp of very big growth.

ADAP Crosses Above Average Analyst Target

ADAP Crosses Above Average Analyst Target

In recent trading, shares of Adaptimmune Therapeutics PLC have crossed above the average analyst 12-month target price of $10.20, changing hands for $10.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Adaptimmune Announces Responses In Second Solid Tumor Indication With NY-ESO SPEAR T-cells

Adaptimmune Announces Responses In Second Solid Tumor Indication With NY-ESO SPEAR T-cells

Data provides confirmation of broad applicability of SPEAR TCR T-cell platform in solid tumors

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Immunotherapy M&A In Focus as Celgene Buys Juno; Good, Bad of Activism--ICYMI

Here's what you need to know now for Monday, Jan. 22.

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Immunotherapy Stocks Power Higher on Celgene-Juno Deal

Shares of immunotherapy companies including Ziopharm Oncology and Fate Therapeutics rose early on Monday on the heels of Juno Therapeutics' announced sale to Celgene.

First Week of February 16th Options Trading For Adaptimmune Therapeutics (ADAP)

First Week of February 16th Options Trading For Adaptimmune Therapeutics (ADAP)

Investors in Adaptimmune Therapeutics PLC saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ADAP options chain for the new February 16th contracts and identified one put and one call contract of particular interest.

Adaptimmune Announces Two Manufacturing Achievements On Its Way To Become The First Fully Integrated TCR T-cell Therapy Company

Adaptimmune Announces Two Manufacturing Achievements On Its Way To Become The First Fully Integrated TCR T-cell Therapy Company

Successful Manufacturing of SPEAR T-cells for a Patient at its Navy Yard Site and Agreement with Cell and Gene Therapy Catapult to Increase Vector Manufacturing Capacity

TheStreet Quant Rating: D (Sell)